Ionis Pharmaceuticals, Inc. (IONS) SVP Elizabeth L. Hougen Sells 7,000 Shares
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP Elizabeth L. Hougen sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $54.35, for a total value of $380,450.00. Following the transaction, the senior vice president now directly owns 17,392 shares in the company, valued at $945,255.20. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of Ionis Pharmaceuticals, Inc. (NASDAQ IONS) traded down $0.21 on Friday, reaching $54.15. The company’s stock had a trading volume of 416,997 shares, compared to its average volume of 1,494,890. The company has a debt-to-equity ratio of 1.50, a current ratio of 6.25 and a quick ratio of 6.21. The company has a market cap of $6,760.00, a price-to-earnings ratio of 356.87 and a beta of 2.89. Ionis Pharmaceuticals, Inc. has a 1 year low of $37.26 and a 1 year high of $65.51.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.watchlistnews.com/ionis-pharmaceuticals-inc-ions-svp-elizabeth-l-hougen-sells-7000-shares/1710449.html.
A number of research analysts recently weighed in on the company. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.00 price target on the stock in a research note on Tuesday, October 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Tuesday, October 17th. Stifel Nicolaus reaffirmed a “hold” rating and set a $50.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and set a $30.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, October 6th. Finally, Barclays PLC assumed coverage on Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They set an “equal weight” rating and a $55.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $50.31.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Iguana Healthcare Management LLC bought a new stake in Ionis Pharmaceuticals during the 3rd quarter worth approximately $761,000. Parallel Advisors LLC grew its holdings in shares of Ionis Pharmaceuticals by 60.3% in the third quarter. Parallel Advisors LLC now owns 3,323 shares of the company’s stock valued at $182,000 after acquiring an additional 1,250 shares in the last quarter. California Public Employees Retirement System grew its holdings in shares of Ionis Pharmaceuticals by 1.6% in the third quarter. California Public Employees Retirement System now owns 222,900 shares of the company’s stock valued at $11,301,000 after acquiring an additional 3,600 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $1,268,000. Finally, Crestline Management LP bought a new position in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $2,584,000. 88.98% of the stock is owned by hedge funds and other institutional investors.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.